Also known as Verzenio.
Q3 revenue rose 39% to $24.4B; 2026 revenue outlook raised to $91–$92B. Q3 included ~$900M of benefits and $4.2B IPR&D charges; multiple FDA approvals and positive late‑stage readouts reported.
FDA grants full approval to the all‑oral imlunestrant + abemaciclib combination for adults with ER+, HER2–, ESR1‑mutated advanced or metastatic breast cancer after prior endocrine therapy.
Inluriyo™ improves survival in ER+, HER2- breast cancer, both alone and with abemaciclib, extending time to chemotherapy and showing durable benefits across patient groups.
